Trachoma cost-effectiveness of therapy

Trachoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Trachoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Trachoma cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Trachoma cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Trachoma cost-effectiveness of therapy
CDC on Trachoma cost-effectiveness of therapy
Trachoma cost-effectiveness of therapy in the news
Blogs on Trachoma cost-effectiveness of therapy
Directions to Hospitals Treating Trachoma
Risk calculators and risk factors for Trachoma cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Cost-Effectiveness of Therapy

Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.

References

Template:WikiDoc Sources